Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G-NiiB Microbiome Liver Metabolism Formula
- Development stage
- Unknown
- Lead developer
- GenieBiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
G-NiiB Microbiome Liver Metabolism Formula (SLD07) is a synbiotic dietary supplement developed by GenieBiome, a biotechnology company founded by faculty from The Chinese University of Hong Kong. The product features a proprietary 3+3 formulation, consisting of three specific probiotic strains (typically from the Bifidobacterium genus) and three prebiotic fibers. It is designed to support liver health by modulating the gut-liver axis, restoring microbial balance in the intestines, and potentially reducing metabolic endotoxemia and systemic inflammation. The formula is primarily targeted at individuals seeking to support liver metabolism and manage conditions associated with metabolic dysregulation, such as non-alcoholic fatty liver disease (NAFLD).
- Brand names
- G-NiiB Microbiome Liver Metabolism FormulaG-NiiB 微生態纖肝代謝配方
- Other names
- Microbiome Liver Metabolism FormulaG-NiiB Liver Metabolism Support
Beyond the preview
Go deeper on G-NiiB Microbiome Liver Metabolism Formula.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G-NiiB Microbiome Liver Metabolism Formula.